These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32902324)

  • 21. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation.
    Ye Q; Jiang M; Huang WT; Ling Y; Olson SH; Sun D; Xu G; Yan X; Wong BK; Jin L
    Xenobiotica; 2015; 45(8):681-92. PubMed ID: 25798742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition of a low dose of 14C-bisphenol A in male rats and its main biliary excretion as BPA glucuronide.
    Kurebayashi H; Betsui H; Ohno Y
    Toxicol Sci; 2003 May; 73(1):17-25. PubMed ID: 12700409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
    Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.
    Maurer G; Schreier E; Delaborde S; Nufer R; Shukla AP
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):51-62. PubMed ID: 6861794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.
    Macha S; Chen L; Norris SH; Philip E; Mao Y; Silverstein H; Struble C; Beers W
    J Pharm Pharmacol; 2007 Sep; 59(9):1223-33. PubMed ID: 17883893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
    Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
    Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways.
    Dalvie DK; Khosla NB; Navetta KA; Brighty KE
    Drug Metab Dispos; 1996 Nov; 24(11):1231-40. PubMed ID: 8937858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
    Zamek-Gliszczynski MJ; Abraham TL; Alberts JJ; Kulanthaivel P; Jackson KA; Chow KH; McCann DJ; Hu H; Anderson S; Furr NA; Barbuch RJ; Cassidy KC
    Drug Metab Dispos; 2013 Apr; 41(4):714-26. PubMed ID: 23305709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erdafitinib to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats.
    Paulson SK; Zhang JY; Breau AP; Hribar JD; Liu NW; Jessen SM; Lawal YM; Cogburn JN; Gresk CJ; Markos CS; Maziasz TJ; Schoenhard GL; Burton EG
    Drug Metab Dispos; 2000 May; 28(5):514-21. PubMed ID: 10772629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
    Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
    J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipatasertib (GDC-0068) and erdafitinib co-treatment for inducing mitochondrial apoptosis through Bim upregulation in bladder cancer cells.
    Hu C; Shang X; Zheng T; Hu X; Zhao Y
    Biochem Biophys Res Commun; 2022 May; 604():165-171. PubMed ID: 35306249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs.
    Ohtsu Y; Gibbons JA; Suzuki K; Fitzsimmons ME; Nozawa K; Arai H
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):611-626. PubMed ID: 27590197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.
    Wright LC; Maia J; Loureiro AI; Almeida L; Soares-Da-Silva P
    Drug Metab Lett; 2010 Aug; 4(3):149-62. PubMed ID: 20642448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.
    Dockens RC; Santone KS; Mitroka JG; Morrison RA; Jemal M; Greene DS; Barbhaiya RH
    Drug Metab Dispos; 2000 Aug; 28(8):973-80. PubMed ID: 10901709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat.
    Mountfield RJ; Kiehr B; John BA
    Drug Metab Dispos; 2000 May; 28(5):503-13. PubMed ID: 10772628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
    Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
    Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
    Ling J; Johnson KA; Miao Z; Rakhit A; Pantze MP; Hamilton M; Lum BL; Prakash C
    Drug Metab Dispos; 2006 Mar; 34(3):420-6. PubMed ID: 16381666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
    Waters NJ; Smith SA; Olhava EJ; Duncan KW; Burton RD; O'Neill J; Rodrigue ME; Pollock RM; Moyer MP; Chesworth R
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):43-62. PubMed ID: 26645404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.